Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma

Table 2 Stepwise multiple regression analysis to predict the decreased body weoght (%)

Variables	Coefficient	95%CI	F	P value
For all patients
HCC (-/+)	-1.2734	(-2.4886, -0.0581)	4.3995	0.0403
Ln (LDH)	-2.7773	(-5.7547, 0.2000)	3.4866	0.0669
For the patients with HCC
Furosemide (≤ 40 mg vs > 40 mg/d)	-2.0574	(-0.2775, -3.8373)	5.5889	0.0250
T-factor (T1 and T2 vs T3)	-1.6036	(-0.0932, 3.3494)	3.7494	0.0629
For the patients without HCC
Furosemide (≤ 20 mg vs > 20 mg/d)	2.0854	(3.8667, 0.3040)	5.8379	0.0237
CPT score	1.4320	(0.3801, 2.4839)	7.8941	0.0097
Ln (LDH)	-6.2691	(-11.0598, -1.4786)	7.2950	0.0125

For all patients: Decreased BW% = 19.3220 - 1.2734 [HCC (-/+)] - 2.7773 [Ln (LDH)], R2 = 0.1334, P = 0.0157, [HCC (-) = -1, HCC (+) = 1]; For the patients with HCC: Decreased BW% = 1.5085 - 1.9322 (T factor) - 2.3751 (Furosemide), R2 = 0.2570, P = 0.0135, (T1 and T2 = -1, T3 = 1), (Furosemide ≤ 40 mg/d = -1, Furosemide > 40 mg/d = 1); For the patients without HCC: Decreased BW% = 22.9810 + 2.0854 (Furosemide) + 1.4320 (CPT score) - 6.2691 [Ln (LDH)], R2 = 0.3379, P = 0.0178 (Furosemide ≤ 20 mg/d = -1, Furosemide > 20 mg/d = 1). CPT score: Child-Pugh-Turcotte score; HCC: Hepatocellular carcinoma; LDH: Lactate dehydrogenase.